Global Non-Steroidal Anti-Inflammatory Drugs Market Growth (Status and Outlook) 2023-2029

Global Non-Steroidal Anti-Inflammatory Drugs Market Growth (Status and Outlook) 2023-2029

The global Non-Steroidal Anti-Inflammatory Drugs market size is projected to grow from US$ 20150 million in 2022 to US$ 29430 million in 2029; it is expected to grow at a CAGR of 5.6% from 2023 to 2029.

United States market for Non-Steroidal Anti-Inflammatory Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Non-Steroidal Anti-Inflammatory Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Non-Steroidal Anti-Inflammatory Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Non-Steroidal Anti-Inflammatory Drugs players cover Pfizer Inc., Bayer AG, GSK plc, Dr. Reddy’s Laboratories Ltd, Viatris Inc, Teva Pharmaceutical Industries Ltd., Johnson And Johnson Services, Inc. and Merck & Co., Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

Non-Steroidal Anti-Inflammatory Drugs are members of a therapeutic drug class which reduces pain, decreases inflammation, decreases fever,[1] and prevents blood clots. Side effects depend on the specific drug, its dose and duration of use, but largely include an increased risk of gastrointestinal ulcers and bleeds, heart attack, and kidney disease.

LPI (LP Information)' newest research report, the “Non-Steroidal Anti-Inflammatory Drugs Industry Forecast” looks at past sales and reviews total world Non-Steroidal Anti-Inflammatory Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Non-Steroidal Anti-Inflammatory Drugs sales for 2023 through 2029. With Non-Steroidal Anti-Inflammatory Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Non-Steroidal Anti-Inflammatory Drugs industry.

This Insight Report provides a comprehensive analysis of the global Non-Steroidal Anti-Inflammatory Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Non-Steroidal Anti-Inflammatory Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Non-Steroidal Anti-Inflammatory Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non-Steroidal Anti-Inflammatory Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non-Steroidal Anti-Inflammatory Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Non-Steroidal Anti-Inflammatory Drugs market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Non-Selective NSAIDs
COX-2 Selective NSAIDs

Segmentation by application
Dental Pain
Muscle Aches
Pain caused by Gout
Bursitis
Menstrual Cramps
Fever
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer Inc.
Bayer AG
GSK plc
Dr. Reddy’s Laboratories Ltd
Viatris Inc
Teva Pharmaceutical Industries Ltd.
Johnson And Johnson Services, Inc.
Merck & Co., Inc.



Please note: The report will take approximately 2 business days to prepare and deliver.